Literature DB >> 22863666

N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Bai Lei1, Daisuke Nakano, Yoshihide Fujisawa, Ya Liu, Hirofumi Hitomi, Hiroyuki Kobori, Hirohito Mori, Tsutomu Masaki, Katsuhiko Asanuma, Yasuhiko Tomino, Akira Nishiyama.   

Abstract

We recently demonstrated that cilnidipine, an L/N-type calcium channel blocker, elicits protective effects against glomerular podocyte injury, in particular, in obese hypertensive rats that express the N-type calcium channel (N-CC). Since the N-CC is known to be expressed in sympathetic nerve endings, we evaluated the reno-protective effects of cilnidipine in innervated and denervated spontaneously hypertensive rats (SHR). Male SHR were uninephrectomized and fed 4% high-salt diet (HS-UNX-SHR). Animals were divided into groups, as follows, and observed from 9 to 27 weeks of age: 1) vehicle (n = 14), 2) vehicle plus renal-denervation (n = 15), 3) cilnidipine (50 mg/kg per day, p.o.; n = 10), and 4) cilnidipine plus renal-denervation (n = 15). Renal denervation attenuated elevations in blood pressure, but failed to suppress urinary protein excretion and podocyte injury in HS-UNX-SHR. Cilnidipine in both innervated and denervated HS-UNX-SHR similarly induced significant antihypertensive effects, as well as suppressing the urinary protein excretion and podocyte injury, compared to vehicle-treated HS-UNX-SHR. These data indicate that renal nerves have a limited contribution to the cilnidipine-induced reno-protective effects in HS-UNX-SHR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863666      PMCID: PMC3443282          DOI: 10.1254/jphs.12075fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  46 in total

1.  Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.

Authors:  Yu-Yan Fan; Ryoko Baba; Yukiko Nagai; Akira Miyatake; Naohisa Hosomi; Shoji Kimura; Guang-Ping Sun; Masakazu Kohno; Mamoru Fujita; Youichi Abe; Akira Nishiyama
Journal:  Hypertens Res       Date:  2006-03       Impact factor: 3.872

2.  Role of the renal nerves in blood pressure in male and female SHR.

Authors:  Radu Iliescu; Licy L Yanes; William Bell; Terry Dwyer; Ovidiu C Baltatu; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09-15       Impact factor: 3.619

3.  Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling.

Authors:  Katsuhiko Asanuma; Etsuko Yanagida-Asanuma; Christian Faul; Yasuhiko Tomino; Kwanghee Kim; Peter Mundel
Journal:  Nat Cell Biol       Date:  2006-04-16       Impact factor: 28.824

4.  Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons.

Authors:  L D Hirning; A P Fox; E W McCleskey; B M Olivera; S A Thayer; R J Miller; R W Tsien
Journal:  Science       Date:  1988-01-01       Impact factor: 47.728

5.  The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.

Authors:  Tomoyuki Konda; Azusa Enomoto; Junko Matsushita; Akira Takahara; Toshiki Moriyama
Journal:  Nephron Physiol       Date:  2005-05-09

6.  Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1.2) Ca2+ channels.

Authors:  Nicole E Pardo; Ravindra K Hajela; William D Atchison
Journal:  J Pharmacol Exp Ther       Date:  2006-09-18       Impact factor: 4.030

7.  Catecholamines modulate podocyte function.

Authors:  T B Huber; J Gloy; A Henger; P Schollmeyer; R Greger; P Mundel; H Pavenstädt
Journal:  J Am Soc Nephrol       Date:  1998-03       Impact factor: 10.121

8.  Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.

Authors:  K Katayama; S Nomura; H Ishikawa; T Murata; S Koyabu; T Nakano
Journal:  Kidney Int       Date:  2006-05-17       Impact factor: 10.612

9.  Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs.

Authors:  A Takahara; H Dohmoto; H Hisa; S Satoh; R Yoshimoto
Journal:  Jpn J Pharmacol       Date:  1997-09

10.  Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.

Authors:  Tomoyuki Konda; Azusa Enomoto; Akira Takahara; Hiroshi Yamamoto
Journal:  Biol Pharm Bull       Date:  2006-05       Impact factor: 2.233

View more
  5 in total

1.  Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.

Authors:  Natanong Thamcharoen; Paweena Susantitaphong; Supakanya Wongrakpanich; Pakawat Chongsathidkiet; Pakpoom Tantrachoti; Siwadon Pitukweerakul; Yingyos Avihingsanon; Kearkiat Praditpornsilpa; Bertrand L Jaber; Somchai Eiam-Ong
Journal:  Hypertens Res       Date:  2015-07-02       Impact factor: 3.872

2.  Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.

Authors:  Keisuke Ohnishi; Miki Murase; Daisuke Nakano; Nicolas Pelisch; Hirofumi Hitomi; Hiroyuki Kobori; Satoshi Morimoto; Hirohito Mori; Tsutomu Masaki; Koji Ohmori; Masakazu Kohno; Atsuhiro Ichihara; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2013-05-22       Impact factor: 3.337

3.  Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure.

Authors:  Shoko Ohno; Hideki Yokoi; Kiyoshi Mori; Masato Kasahara; Koichiro Kuwahara; Junji Fujikura; Masaki Naito; Takashige Kuwabara; Hirotaka Imamaki; Akira Ishii; Moin A Saleem; Tomohiro Numata; Yasuo Mori; Kazuwa Nakao; Motoko Yanagita; Masashi Mukoyama
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

4.  Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel.

Authors:  Keiichiro Mishima; Masao Nakasatomi; Shunsuke Takahashi; Hidekazu Ikeuchi; Toru Sakairi; Yoriaki Kaneko; Keiju Hiromura; Yoshihisa Nojima; Akito Maeshima
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

Review 5.  Calcium channel blocker in patients with chronic kidney disease.

Authors:  Shoko Ohno; Akira Ishii; Motoko Yanagita; Hideki Yokoi
Journal:  Clin Exp Nephrol       Date:  2021-11-08       Impact factor: 2.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.